You can buy or sell ObsEva and other stocks, options, ETFs, and crypto commission-free!
ObsEva SA engages in the development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. Read More The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
Geneva, Geneve (Geneva)
52 Week High
52 Week Low
Seeking AlphaMay 13
ObsEva SA CEO Ernest Loumaye on Q1 2019 Results - Earnings Call Transcript
ObsEva SA (NASDAQ:OBSV) Q1 2019 Results Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Mario Corso - Senior Director, Investor Relations Ernest Loumaye - Co-Founder and Chief Executive Officer Jean-Pierre Gotteland - Chief Scientific Officer Wim Souverijns - Chief Commercial Officer Tim Adams - Chief Financial Officer Conference Call Participants Justin Burns - RBC Capital Markets Sheldon Fan - SVB Leerink Mark Connolly - Credit Suisse Liana Moussatos - Wedbush Securities D...
Yahoo FinanceMay 9
Here’s What Hedge Funds Think About ObsEva SA (OBSV)
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing winning small-cap stocks.
Seeking AlphaMay 3
ObsEva's linzagolix shows long-term effect in extension study
Long-term data from a Phase 2b clinical trial, EDELWEISS, evaluating ObsEva SA's (NASDAQ:OBSV) linzagolix for the treatment of endometriosis-associated pelvic pain showed a durable treatment benefit with the daily 75 mg and 200 mg doses.
-$0.51 per share
-$0.59 per share